Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models

PLoS One. 2019 May 9;14(5):e0216559. doi: 10.1371/journal.pone.0216559. eCollection 2019.

Abstract

Rationale & objective: Early prediction of chronic kidney disease (CKD) progression to end-stage kidney disease (ESKD) currently use Cox models including baseline estimated glomerular filtration rate (eGFR) only. Alternative approaches include a Cox model that includes eGFR slope determined over a baseline period of time, a Cox model with time varying GFR, or a joint modeling approach. We studied if these more complex approaches may further improve ESKD prediction.

Study design: Prospective cohort.

Setting & participants: We re-used data from two CKD cohorts including patients with baseline eGFR >30ml/min per 1.73m2. MASTERPLAN (N = 505; 55 ESKD events) was used as development dataset, and NephroTest (N = 1385; 72 events) for validation.

Predictors: All models included age, sex, eGFR, and albuminuria, known prognostic markers for ESKD.

Analytical approach: We trained the models on the MASTERPLAN data and determined discrimination and calibration for each model at 2 years follow-up for a prediction horizon of 2 years in the NephroTest cohort. We benchmarked the predictive performance against the Kidney Failure Risk Equation (KFRE).

Results: The C-statistics for the KFRE was 0.94 (95%CI 0.86 to 1.01). Performance was similar for the Cox model with time-varying eGFR (0.92 [0.84 to 0.97]), eGFR (0.95 [0.90 to 1.00]), and the joint model 0.91 [0.87 to 0.96]). The Cox model with eGFR slope showed the best calibration.

Conclusion: In the present studies, where the outcome was rare and follow-up data was highly complete, the joint models did not offer improvement in predictive performance over more traditional approaches such as a survival model with time-varying eGFR, or a model with eGFR slope.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Progression
  • Female
  • Glomerular Filtration Rate
  • Humans
  • Kidney Failure, Chronic / diagnosis*
  • Kidney Failure, Chronic / etiology
  • Kidney Function Tests
  • Male
  • Middle Aged
  • Models, Statistical*
  • Prognosis
  • Prospective Studies
  • Renal Insufficiency, Chronic / complications*
  • Risk Assessment / methods*

Grants and funding

JAJGvdB is supported by grant DKF14OKG07 from the Dutch Kidney Foundation (www.nierstichting.nl); TD was supported by CogIMon H2020 ICT-644727. (https://ec.europa.eu/programmes/horizon2020/en/). The MASTERPLAN Study was supported by grant number PV01 from the Dutch Kidney Foundation (www.nierstichting.nl) and grant 2003B261 from the Netherlands Heart Foundation (Nederlandse Hartstichting, (www.hartstichting.nl). In addition, unrestricted grants were provided by Amgen, Genzyme, Pfizer and Sanofi-Aventis for the MASTERPLAN study. The NephroTest cohort study was supported by the following grants: INSERM (www.inserm.fr) GIS-IReSP AO 8113LS TGIR (B.S.), French Ministry of Health AOM 09114 (M.Fr.), INSERM AO 8022LS (B.S.), Agence de la Biomédecine R0 8156LL (B.S.), AURA (M.Fr.) and Roche 2009-152-447G (M.Fr.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.